Alcon Commercially Launches AcrySof IQ Vivity Extended Depth of Focus IOL in US

Alcon has commercially launched the AcrySof IQ Vivity IOL, which the company describes as the first and only non-diffractive extended depth of focus IOL in the United States.

Vivity is a first-of-its-kind, non-diffractive extended depth of focus IOL with Alcon’s proprietary non-diffractive X-WAVE technology, which stretches and shifts light without splitting it.¹ Vivity delivers monofocal-quality distance with excellent intermediate and functional near vision, according to Alcon.²

To view EyewireTV’s coverage of the launch of the AcrySof IQ Vivity IOL, click here.

“With the introduction of Vivity, Alcon continues to demonstrate our ongoing commitment to growing our IOL portfolio and delivering differentiated innovations that meet surgeon and patient needs,” Sergio Duplan, President, North America at Alcon, said in a company news release. “We now offer two next-generation presbyopia-mitigating IOL options, with the PanOptix Trifocal for patients who want to be more spectacle independent at all distances and Vivity for patients who seek to improve their intermediate and near vision, with a monofocal-like visual disturbance profile.”

Also available in toric designs, Vivity is built on Alcon’s AcrySof IQ IOL platform that has been implanted in more than 125 million eyes globally.⁵ According to results from a U.S. clinical trial, patients who had the Vivity lens implanted experienced renewed vision and lifestyle benefits, including:²

• 94% and 92% of Vivity patients reported very good or good vision at distance and arm’s length, respectively, without glasses in bright light, with vision of 20/20 at distance and greater than 20/25 at intermediate^*†2
• Comparable visual disturbance profile to a monofocal IOL^*2

“The Vivity lens is a disruptive technology that fills a gap for eye surgeons as a presbyopia-mitigating IOL option for those patients who are not candidates for a diffractive IOL platform, but want some spectacle independence,” Cathleen McCabe, MD, Chief Medical Officer, Eye Health America and Medical Director, The Eye Associates, said in the news release. “This lens has a monofocal-like visual disturbance profile, a low incidence of severe or very bothersome glare and halos, and provides a continuous extended range of vision which can meet the needs of many cataract patients.”

Vivity received FDA approval in February 2020, and it was made available to select U.S. ophthalmologists in September 2020 during a pilot phase, ahead of the current national launch.

Vivity is already available in some European markets, Australia, New Zealand and Canada and has been introduced to select ophthalmologists in Latin America. For more information regarding Vivity in the U.S., visit vivityview.com.

References

1. Alcon Data on File, 2019.
2. AcrySof® IQ Vivity™ Extended Vision IOL DFU. Alcon Laboratories, Inc.; 2020.
3. Cataract Data and Statistics. National Eye Institute. Accessed December 21, 2020. https://www.nei.nih.gov/learn-about-eye-health/resources-for-health-educators/eye-health-data-and-statistics/cataract-data-and-statistics.
4. 2020 IOL Market Report – Mid Year Update, Market Scope, 08/28/2020, pp5, Table 47: Forecast for the IOL Market in the United States.
5. Alcon Data on File, 2020.
6. Centers for Disease Control and Prevention, Vision Health Initiative. Accessed December 21, 2020. https://www.cdc.gov/visionhealth/basics/ced/index.html.
7. Cleveland Clinic, Cataracts. Accessed December 21, 2020. https://my.clevelandclinic.org/health/diseases/8589-cataracts.
8. Mayo Clinic, Presbyopia. Accessed December 21, 2020. https://www.mayoclinic.org/diseases-conditions/presbyopia/symptoms-causes/syc-20363328.
9. American Optometric Association: Optometric Clinical Practice Guideline, Care of the Patient with Presbyopia. Accessed December 21, 2020. https://www.aoa.org/documents/optometrists/CPG-17.pdf.

*Results from a prospective, randomized, parallel group, subject- and assessor-masked, multisite trial of 107 subjects bilaterally implanted with the AcrySof® IQ Vivity™ IOL and 113 with the AcrySof® IQ IOL with 6 months’ follow-up

†Response to the following question in IOLSAT questionnaire at 6 months post-op (AcrySof® IQ Vivity™ IOL n = 106, monofocal n = 111): “Given your vision today, would you recommend the lenses you had implanted to your family or friends?”